You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the NEURACEQ (florbetaben f-18) Drug Profile, 2024 PDF Report in the Report Store ~

NEURACEQ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Neuraceq patents expire, and what generic alternatives are available?

Neuraceq is a drug marketed by Life Molecular and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-five patent family members in twenty-seven countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.

DrugPatentWatch® Generic Entry Outlook for Neuraceq

Neuraceq was eligible for patent challenges on March 21, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 18, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for NEURACEQ
International Patents:35
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 5
Clinical Trials: 6
Patent Applications: 105
What excipients (inactive ingredients) are in NEURACEQ?NEURACEQ excipients list
DailyMed Link:NEURACEQ at DailyMed
Drug patent expirations by year for NEURACEQ
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NEURACEQ
Generic Entry Date for NEURACEQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NEURACEQ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Life Molecular Imaging GmbHPhase 3
William Charles KreislPhase 1/Phase 2
Ulsan University HospitalN/A

See all NEURACEQ clinical trials

Pharmacology for NEURACEQ

US Patents and Regulatory Information for NEURACEQ

NEURACEQ is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NEURACEQ is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting NEURACEQ

Stilbene derivatives and their use for binding and imaging amyloid plaques
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Life Molecular NEURACEQ florbetaben f-18 SOLUTION;INTRAVENOUS 204677-001 Mar 19, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NEURACEQ

When does loss-of-exclusivity occur for NEURACEQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 05316421
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0516408
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 91534
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1123995
Estimated Expiration: ⤷  Try a Trial

Costa Rica

Patent: 06
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 13652
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 2334
Estimated Expiration: ⤷  Try a Trial

Patent: 0701299
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 38298
Estimated Expiration: ⤷  Try a Trial

Patent: 41465
Estimated Expiration: ⤷  Try a Trial

Patent: 13652
Estimated Expiration: ⤷  Try a Trial

France

Patent: C0012
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 500014
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 3946
Estimated Expiration: ⤷  Try a Trial

Patent: 6091
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 28956
Estimated Expiration: ⤷  Try a Trial

Patent: 08524243
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 213652
Estimated Expiration: ⤷  Try a Trial

Luxembourg

Patent: 647
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 07007380
Estimated Expiration: ⤷  Try a Trial

Netherlands

Patent: 0719
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 5942
Estimated Expiration: ⤷  Try a Trial

Norway

Patent: 9195
Estimated Expiration: ⤷  Try a Trial

Patent: 073650
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 13652
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 13652
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 4363
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 13652
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0705104
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1321619
Estimated Expiration: ⤷  Try a Trial

Patent: 070093427
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 26655
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 996
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NEURACEQ around the world.

Country Patent Number Title Estimated Expiration
Lithuania C2213652 ⤷  Try a Trial
Japan 2008524243 ⤷  Try a Trial
Japan 4950031 ⤷  Try a Trial
South Korea 101321619 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NEURACEQ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2213652 15C0012 France ⤷  Try a Trial PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140224
2213652 C20150010 00142 Estonia ⤷  Try a Trial PRODUCT NAME: FLORBETABEEN (18F);REG NO/DATE: EU/1/13/906 24.02.2014
2213652 CA 2015 00018 Denmark ⤷  Try a Trial PRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906/001 20140220
2213652 92647 Luxembourg ⤷  Try a Trial PRODUCT NAME: FLORBETABEN (18F). FIRST REGISTRATION: 20140224
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.